Report contents
At a glance
- Business model: monthly cash-pay subscriptions bundle a clinician consultation, prescription and delivery through pharmacies and labs Hims & Hers owns. Revenue reached $0.89 billion in the September 2026 quarter, up 49% year over year. Price cuts are deliberate, so order volume must carry revenue while branded weight-loss supply earns thinner margin than the compounded versions it replaced.
- Financial quality: FY2025 produced $130 million of net income and $300 million of operating cash flow, but nine months of FY2026 brought a $210 million net loss, about $20 million of free cash flow and a 57.2% quarterly gross margin. Long-term debt of $1.37 billion sits against $610 million of cash, with goodwill of $1.11 billion over $350 million of equity. That absorbs a weak year, not a permanent margin reset.
Business model
Business model: a cash-pay subscription built on owned pharmacies
Hims & Hers sells recurring treatment, not one-off visits. A customer signs up online, is matched to a licensed clinician, receives a prescription where appropriate, and pays a monthly fee that bundles the consultation, the medication and delivery. Much of the dispensing runs through pharmacies the company owns. The payer is usually the patient. Most revenue comes from US adults paying cash for conditions that persist: hair loss, erectile dysfunction, dermatology, mental health, weight loss and, more recently, testosterone and lab-monitored hormone therapy. That cash-pay design explains both the growth and the constraint. No insurer has to approve a claim, so sign-up is fast; the customer also sees the full price every month and can cancel with little friction.
The business is best described as a vertically integrated consumer health brand in an expansion stage. It holds no proprietary molecule, yet it controls the parts of the chain that set cost and speed: the clinician network, the pharmacy, the lab testing, and the brand that acquires the customer. Andrew Dudum, the chief executive, wrote in a November 9, 2026 company post that "whoever owns that relationship wins" and that the model rests on "operational rigor to run our own pharmacies and labs." The strategic bet is that owning fulfillment turns a marketing business into an operating one, and that the same customer can be sold the next condition without paying acquisition costs twice.
Price cuts are the plan, so volume must carry revenue
The clearest economics statement in the company's own commentary is deflationary. Management says that as pharmacy and lab infrastructure scales, "we intend to pass those savings on to customers, either through lower prices or with more included for the same price." Canada is the worked example: generics arrived there in 2026, and the company says average monthly orders grew more than 50% after launch.
Cheaper drugs, more orders, and similar gross profit per order only if fulfillment cost falls fast enough. The arithmetic is unforgiving. If the price per order falls 30% and orders rise 50%, revenue grows but profit per order may not, and the model needs a wider customer base to produce the same earnings. Hims has not disclosed revenue by category, so it is impossible to test from outside whether generic-era weight-loss orders are accretive or dilutive to gross profit.
Weight loss carries a second exposure. Management describes its relationships with Eli Lilly and Novo Nordisk as underpinning "a broad assortment," which means part of the category now runs on branded drugs supplied by manufacturers that also sell directly to consumers. Carrying a branded product likely earns a thinner margin than dispensing through the company's own pharmacy, though that is an inference the disclosure does not settle.
International is a second acquisition engine, and a young one
The Eucalyptus acquisition produced $233 million of international revenue in its first full quarter, more than four times the year-earlier level, and management is targeting a $1 billion annual run rate in 2027. Since August the company has moved the Eucalyptus brands onto the Hims & Hers name and launched Hims and Hers in Australia, Hers Hair in the UK and Hims in Germany. That is real distribution progress in markets where the US cash-pay formula had no footprint.
Two cautions attach. The 4x comparison comes off a tiny base, and the $1 billion figure is a management target rather than a reported result. More important, launches measure customer acquisition, not customer persistence. A market can post strong first-quarter revenue on promotional pricing and still fail the test that matters: whether subscribers renew at US-like rates once the introductory offer ends. The company does not publish country-level retention.
Scale is asserted more than disclosed
Management cites a brand that "close to 3 million people trust," roughly nine years of investment, and new specialties including testosterone, approaching a $100 million annualized revenue run rate, and Peptides+ with clinician-led monitoring. The cross-sell premise is that one acquired customer buys hair loss, then weight loss, then hormone therapy, so marketing spend per dollar of revenue declines as the relationship ages.
The disclosure does not let an outsider verify that. Hims reports total customers and aggregate revenue, not multi-specialty attach rates, cohort retention or revenue per customer by tenure. Until those numbers appear, the attach story rests on management commentary and on the pace of new specialty launches. What would overturn the main judgment is straightforward: if order growth in genericized categories arrives alongside falling revenue per customer and rising sales and marketing spend per new subscriber, the portfolio is acting like several separate acquisition funnels sharing a brand, and the operating leverage is illusory. If revenue per customer holds while order counts climb, the deflation strategy is working as designed.
Questions worth following
- Can weight-loss orders keep growing as generics reset prices?
Weight loss is the largest category pulling new customers onto the platform, and management says Canadian orders rose more than 50% once generics launched. If per-order revenue falls faster than volume rises, the category adds customers without adding profit, and the cross-sell thesis loses its entry point.
- Can Hims build a repeat-purchase base outside the US?
International revenue reached $233 million in the first full quarter with Eucalyptus, and management targets a $1 billion annual run rate in 2027. Whether those customers resubscribe determines if overseas expansion produces durable revenue or just repeats acquisition spending in each new market.
- Do new customers add a second category within a year?
The platform argument rests on one acquired customer buying hair loss, then weight loss, then hormone therapy, so marketing cost per dollar of revenue declines as the relationship ages. Without attach, Hims is a set of separate acquisition funnels sharing a brand.
Financial quality
Financial quality: growth now costs margin and cash
Hims & Hers Health still turns most of its revenue into gross profit and still produces operating cash, but the quality of those earnings has weakened sharply over the past year. FY2025 closed with $2.35 billion of revenue, $130 million of net income and $300 million of operating cash flow. The first nine months of FY2026 produced a $210 million net loss and about $20 million of free cash flow, on revenue the company guided to grow 33–34% for the full year in its November 2026 update. Growth is now being bought with price, product mix and debt.
Margins: revenue is outrunning the profit it carries
Gross margin fell from 73.8% in FY2025 to 57.2% in the September 2026 quarter, with a 49.4% trough in the March quarter. Revenue rose 49% year over year in Q3, but gross profit rose only about 16%, from $440 million to $510 million. Management tied the slide to integrating the international acquisition and to branded GLP-1 deals that carry thinner product margin than the compounded versions the business was built on. That reads as a structural mix change, not a bad quarter: the earlier 80% margins came from a narrow, cash-pay catalog, and a broader one with branded drugs and international operations will not restore them. Net margin followed gross margin from 8.5% in FY2024 to 5.5% in FY2025 to -3.7% in Q3 FY2026.
The 30.7% and 25.2% returns on equity in FY2024 and FY2025 were earned on $480–540 million of equity with no debt. Those returns have gone negative as losses accumulated and the equity base was thinned, so the historical ROE says more about a small denominator than durable profitability.
Cash: operating cash holds, free cash flow thins
Operating cash covered net income 1.9 times in FY2024 and 2.3 times in FY2025, which is what a prepaid subscription model should do. That held through the losses: $120 million of operating cash in the first nine months of FY2026 against the $210 million net loss, helped by non-cash charges and by about $18 million of weight-loss membership revenue that slid from Q3 into Q4. Capex also stepped up, to an implied $230 million in FY2025 from $50 million a year earlier, which cut free cash flow to $70 million despite record operating cash. Against a $3.1 billion revenue base that is a thin free cash flow margin of roughly 2%. Management expects positive free cash flow in 2026 and 2027; the first nine months leave little cushion.
The balance sheet now carries the strategy
Long-term debt went from nothing at the end of FY2024 to $970 million by the June 2025 quarter and $1.37 billion by September 2026, against $610 million of cash. Goodwill jumped from $340 million to $1.10 billion in the June 2026 quarter when the international acquisition closed, so goodwill is now more than three times book equity of $350 million. Total liabilities at 38.9% of assets looks unremarkable, but the current ratio fell to 0.92 and the quick ratio to 0.84, meaning current liabilities exceed current assets. Some of that gap is deferred revenue, the least dangerous liability for a subscription model, and the data do not split it out — so the liquidity read is cautious, not alarming.
Asset turnover tells the reinvestment story: 2.57 in FY2024, 1.64 in FY2025, roughly 1.0 annualized in FY2026. The company roughly doubled its asset base while revenue grew 33%, so the return on that capital depends on international and new-category revenue scaling on assets bought at a premium.
Three things to check
- Receivables. They reached $430 million at September 30, 2026, from $30 million a year earlier: about 44 days of the quarter's revenue versus roughly 6 days. Either international or partner billing changed the collection model, or cash is arriving later than revenue. The answer decides how much of the cash conversion above is durable.
- Adjusted versus GAAP. Q3 adjusted EBITDA was $82 million, a 9% margin, against a $70 million GAAP operating loss. A gap that size in one quarter needs the reconciliation — stock compensation, integration costs, amortization of acquired intangibles — before adjusted EBITDA can stand in for earnings.
- Goodwill and the notes. An impairment against $1.11 billion of goodwill would be severe relative to $350 million of equity. The income statement also shows no meaningful interest expense against $1.37 billion of long-term debt, which points to a low-coupon convertible; the conversion terms and potential dilution are worth reading.
Annual metrics and latest quarter
USD bn unless stated; FY2021–FY2025 are full years, the final data column is the quarter ended September 30, 2026.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Q3 FY2026 | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue | 0.27 | 0.53 | 0.87 | 1.48 | 2.35 | 0.89 | Strong |
| Gross margin | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% | 57.2% | Adequate, falling |
| Net margin | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% | -3.7% | Weak |
| ROE | -114.7% | -20.3% | -7.2% | 30.7% | 25.2% | -9.7% | Very weak |
| ROA | -39.9% | -16.7% | -5.8% | 21.9% | 9.0% | -0.9% | Weak |
| Liabilities/assets | 20.4% | 14.9% | 22.0% | 32.6% | 45.4% | 38.9% | Adequate, rising |
| Current ratio | 3.41 | 4.52 | 3.00 | 1.79 | 1.90 | 0.92 | Weak |
| Quick ratio | 3.24 | 4.07 | 2.74 | 1.50 | 1.61 | 0.84 | Weak |
| Asset turnover | 1.01 | 1.34 | 2.16 | 2.57 | 1.64 | 0.25 | Adequate, falling |
| Inventory turnover | 7.88 | 6.73 | 7.13 | 6.98 | 6.82 | 3.90 | Strong |
| Receivables turnover | 125.7 | 154.8 | 174.8 | 230.2 | 122.8 | 2.2 | Weak |
| Operating cash flow | -0.03 | -0.03 | 0.07 | 0.25 | 0.30 | 0.07 | Strong |
| Free cash flow | -0.04 | -0.03 | 0.05 | 0.20 | 0.07 | 0.03 | Adequate, thinning |
| Capex, implied | 0.01 | 0.00 | 0.02 | 0.05 | 0.23 | 0.04 | Rising |
| OCF/net income | n/m | n/m | n/m | 1.9x | 2.3x | n/m | Strong |
*Single-quarter figures, not annualized. Quarterly turnover ratios are not comparable with the annual figures above; they are shown to make the receivables jump visible.
Quarterly metrics
USD bn unless stated. Net PP&E is not disclosed for these periods.
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.59 | 0.55 | 0.60 | 0.62 | 0.61 | 0.75 | 0.89 | Strong | Accelerating |
| Net income | 0.05 | 0.04 | 0.02 | 0.02 | -0.09 | -0.09 | -0.03 | Weak | Losses narrowing |
| Total assets | 0.89 | 1.88 | 2.23 | 2.16 | 2.27 | 3.63 | 3.55 | Adequate | Step-up on acquisition |
| Total liabilities | 0.34 | 1.31 | 1.65 | 1.61 | 1.82 | 3.30 | 3.19 | Demanding | Rising with debt |
| Net PP&E | n/d | n/d | n/d | n/d | n/d | n/d | n/d | Not disclosed | Not disclosed |
| Goodwill | 0.12 | 0.12 | 0.26 | 0.28 | 0.34 | 1.10 | 1.11 | Weak | Up sharply |
| Operating cash flow | 0.11 | -0.02 | 0.15 | 0.07 | 0.09 | -0.04 | 0.07 | Adequate | Volatile |
| Gross margin | 73.5% | 76.4% | 73.8% | 71.9% | 49.4% | 63.8% | 57.2% | Weak | Down |
| Current ratio | 1.59 | 4.98 | 1.88 | 1.90 | 1.69 | 0.93 | 0.92 | Weak | Falling |
The 4.98 current ratio in Q2 2025 followed an $890 million financing inflow and preceded an $890 million investing outflow; it reflects where cash sat that quarter, not a lasting liquidity gain.
Questions worth following
- Can Hims & Hers hold GLP-1 margins as manufacturers sell direct?
Weight-loss drugs drive most of the growth, and the shift toward branded products moves margin to the manufacturers. If Hims & Hers cannot hold a spread between what it pays and what customers pay, revenue growth produces less gross profit and the multiple on adjusted EBITDA compresses.
- Will recurring free cash flow cover Hims & Hers' $1.4 billion debt?
The company moved from no debt to $1.37 billion in about a year while goodwill rose to more than three times book equity. If recurring cash covers interest and refinancing, the balance sheet supports the expansion; if not, growth depends on new financing or share issuance.
- Does Hims & Hers' cash conversion depend on membership prepayments?
Operating cash flow has run well ahead of GAAP earnings, helped by deferred membership revenue and non-cash charges. If that gap is mostly timing of customer prepayments, cash conversion weakens once enrollment slows, and adjusted profitability becomes a poorer guide to the cash the business actually throws off.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Hims Hers Health Inc
Hims Hers Health Inc
Business, moat and key questions
Open company page